489 related articles for article (PubMed ID: 22247021)
1. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract][Full Text] [Related]
2. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Uras IZ; Moll HP; Casanova E
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Tomasini P; Walia P; Labbe C; Jao K; Leighl NB
Oncologist; 2016 Dec; 21(12):1450-1460. PubMed ID: 27807303
[TBL] [Abstract][Full Text] [Related]
5. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
6. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Salgia R; Pharaon R; Mambetsariev I; Nam A; Sattler M
Cell Rep Med; 2021 Jan; 2(1):100186. PubMed ID: 33521700
[TBL] [Abstract][Full Text] [Related]
7. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
[TBL] [Abstract][Full Text] [Related]
8. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Saturno G; Lopes F; Niculescu-Duvaz I; Niculescu-Duvaz D; Zambon A; Davies L; Johnson L; Preece N; Lee R; Viros A; Holovanchuk D; Pedersen M; McLeary R; Lorigan P; Dhomen N; Fisher C; Banerji U; Dean E; Krebs MG; Gore M; Larkin J; Marais R; Springer C
Ann Oncol; 2021 Feb; 32(2):269-278. PubMed ID: 33130216
[TBL] [Abstract][Full Text] [Related]
9. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
[TBL] [Abstract][Full Text] [Related]
10. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Nardi F; Perurena N; Schade AE; Li ZH; Ngo K; Ivanova EV; Saldanha A; Li C; Gokhale PC; Hata AN; Barbie DA; Paweletz CP; Jänne PA; Cichowski K
J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384411
[TBL] [Abstract][Full Text] [Related]
11. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of
Wang MM; Zhang Y; Wu S; Zhang SY; Shan HL; Yang XM; Xu X; Song LQ; Qu SY
Transl Lung Cancer Res; 2023 Oct; 12(10):2030-2039. PubMed ID: 38025817
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.
Hiraki M; Nishimura J; Takahashi H; Wu X; Takahashi Y; Miyo M; Nishida N; Uemura M; Hata T; Takemasa I; Mizushima T; Soh JW; Doki Y; Mori M; Yamamoto H
Mol Ther Nucleic Acids; 2015 Mar; 4(3):e231. PubMed ID: 25756961
[TBL] [Abstract][Full Text] [Related]
14. Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.
Zdanov S; Mandapathil M; Abu Eid R; Adamson-Fadeyi S; Wilson W; Qian J; Carnie A; Tarasova N; Mkrtichyan M; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Res; 2016 Apr; 4(4):354-65. PubMed ID: 26880715
[TBL] [Abstract][Full Text] [Related]
15. Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment.
Pelos G; Riester M; Pal J; Myacheva K; Moneke I; Rotondo JC; Lübbert M; Diederichs S
Int J Cancer; 2024 Mar; 154(6):1029-1042. PubMed ID: 37947765
[TBL] [Abstract][Full Text] [Related]
16. Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer.
Hamilton G; Stickler S; Rath B
Explor Target Antitumor Ther; 2023; 4(5):1027-1038. PubMed ID: 38023987
[TBL] [Abstract][Full Text] [Related]
17. Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor.
Dorr C; Janik C; Weg M; Been RA; Bader J; Kang R; Ng B; Foran L; Landman SR; O'Sullivan MG; Steinbach M; Sarver AL; Silverstein KA; Largaespada DA; Starr TK
Mol Cancer Res; 2015 Aug; 13(8):1238-47. PubMed ID: 25995385
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health.
Ghosh S; Bhuniya T; Dey A; Koley M; Roy P; Bera A; Gol D; Chowdhury A; Chowdhury R; Sen S
Appl Biochem Biotechnol; 2023 Oct; ():. PubMed ID: 37897621
[TBL] [Abstract][Full Text] [Related]
19. New Horizons in
Yang H; Liang SQ; Schmid RA; Peng RW
Front Oncol; 2019; 9():953. PubMed ID: 31612108
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
de Castro Carpeño J; Belda-Iniesta C
Transl Lung Cancer Res; 2013 Apr; 2(2):142-51. PubMed ID: 25806225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
